Look at LinkedIn! Maybe the same will happen to ATHN. Hopefully!
11.00pm-11.30pm: Dr Elisabetta Chiarparin
Astex Pharmaceuticals, Cambridge Science Park, Milton Road, Cambridge, UK
Title: Fragment screening: an Astex perspective
Thank you general. roosevelt. Your posts display the stupidity and desperation of the shorts!
You're becoming a broken record. OK, so you made one good call on the short. However, you're lousy when it comes to making money on the upside. Anyone following your advice in the past few weeks missed out on a huge gain.
Second line approval does not mean that the drug can not be used for first line. It just can't be promoted for first line. Oncologists will prescribe the drug based on its merits.
It's up today for the same reason it hit new highs last week: a great pipeline. Personally, I don't understand why it sold off so much the last few days. Was it because of the idiotic downgrade by The Street?
You're referring to the beat on revenues? What was the guidance or whisper on earnings? Cash looks good! Thanks.